Loading organizations...
§ Private Profile · Sydney, Australia
Bioprinting technology company developing 3D bioprinting for human tissues and cellular models to accelerate drug discovery.
Inventia Life Science, a Sydney, Australia-based company, develops 3D bioprinting technology that creates life-like human tissues and cellular models for pharmaceutical and medical research. Its flagship Rastrum platform is utilized by drug developers, including four of the top 10 global pharmaceutical companies, to test drug candidates in realistic cellular environments, aiming to accelerate drug discovery and reduce failure rates. The company has raised approximately AU$45 million in total funding, including AU$35 million in Series B. It employs 51-100 individuals across its operations in Australia and the United States. Co-founded by Dr. Julio Ribeiro (CEO), Cameron Ferris (COO), and Aidan O'Mahony (CTO), Inventia Life Science was established in 2013. Reported scale details include 51-100 employees, AU$45 million in total funding raised, operates internationally with presence in Australia and the United States.
Inventia Life has raised $25.0M across 1 funding round.
Inventia Life has raised $25.0M in total across 1 funding round.
Inventia Life Science is a Sydney-based biotechnology company developing advanced 3D bioprinting platforms to revolutionize biomedical research, drug development, and regenerative medicine.[1][2][4] It builds the RASTRUM bioprinter for creating scalable 3D cell-based assays and human tissue models, alongside the LIGO surgical tool for in-situ tissue reconstruction, serving researchers, pharmaceutical companies, and clinicians globally.[1][3][4] These tools address key limitations in traditional 2D cell cultures by enabling precise, reproducible 3D models that mimic human biology, accelerating discoveries in tissue repair and personalized medicine while showing strong growth through rapid commercialization and international adoption.[1][4][5]
Inventia Life Science was founded in 2013 in Alexandria, Sydney, Australia, emerging from over 15 years of pioneering research in 3D bioprinting.[2][3][4] Co-founders include Dr. Julio Ribeiro (CEO), a molecular biologist who spearheaded the core technology; Dr. Aidan O'Mahony (CTO), a mechanical engineer previously at Memjet developing high-speed inkjet printers; and Cameron Ferris (COO), with expertise in commercialization from the ARC Centre of Excellence for Electromaterials Science and EY.[3] The idea stemmed from fundamental research to overcome flat, inaccurate 2D cell models, gaining early traction through proprietary bioinks, protocols, and platforms like RASTRUM, backed by NSW Government funding for manufacturing and exports.[1][4]
Inventia rides the 3D bioprinting wave in biotech, fueled by demand for human-relevant models to cut drug development costs and failure rates amid rising precision medicine needs.[1][4][5] Timing aligns with advances in stem cell tech and AI-driven biology, where 3D tissues outperform 2D assays in predicting clinical outcomes, amplified by post-pandemic focus on regenerative therapies.[1][4] Market tailwinds include global pharma's shift to organ-on-chip alternatives and supportive policies like NSW investments, positioning Inventia to influence the ecosystem by enabling faster breakthroughs in tissue engineering and personalized treatments.[4]
Inventia is poised for expansion with RASTRUM Allegro scaling research adoption and LIGO entering clinical trials, potentially capturing surgical bioprinting markets as regulatory approvals accelerate.[4] Trends like AI-optimized bioinks and hybrid human-AI drug screening will amplify its platforms, while global partnerships could drive revenue growth amid a projected $2B+ bioprinting sector.[1][3] Its influence may evolve from research enabler to therapeutic pioneer, transforming how biotech tackles unmet needs in regenerative medicine—echoing its foundational mission to make advanced cell models routine for life-saving innovation.[1][5]
Inventia Life has raised $25.0M in total across 1 funding round.
Inventia Life's investors include Blackbird Ventures Australia, Andreessen Horowitz, Bain Capital Ventures, Better Tomorrow Ventures, Conversion Capital, Daffy, Endure Capital, Fifth Wall, Founders Fund, General Catalyst, QED Investors, Ravelin Capital.
Inventia Life has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $25M Series B | Blackbird Ventures Australia | Andreessen Horowitz, Bain Capital Ventures, Better Tomorrow Ventures, Conversion Capital, Daffy, Endure Capital, Fifth Wall, Founders Fund, General Catalyst, QED Investors, Ravelin Capital, The HIT Forge, Village Global, Y Combinator, ZAK Kukoff, KIM Jackson | Announced |